A unique drug for the treatment of vein diseases enters the Ukrainian market

The pharmaceutical company “Pharmplaneta” presents on the Ukrainian market a new original venotonic “Venoda”, developed by the Austrian company Sanwezza Lab GmbH.

Chronic venous insufficiency is one of the most common problems in modern phlebology. Blue spider veins, unsightly lumpy, enlarged, tortuous and bulging veins, heaviness, pain and fatigue in the legs, swelling, itching, burning, discomfort... Few people are unfamiliar with these symptoms. According to WHO, only about half of women after 40 years of age and about 25% of men suffer from varicose veins of the lower extremities, and about 60% of the adult population of developed countries is predisposed to varicose veins.

Vein diseases are hidden for a long time and do not manifest themselves in the early stages. One of the symptoms - swelling of the legs - occurs more often in the summer, drawing attention to the disease. Therefore, it is no coincidence that it was during the hot season that a new drug “Venoda” appeared in Ukrainian pharmacies - a modern solution to vein problems, proposed by the Austrian company Sanwezza Lab GmbH.

Today there are no analogues of this venotonic drug on the Ukrainian pharmaceutical market. “Austrian developers have proposed a simple but effective solution,” comments Vladimir Semenov, Candidate of Medical Sciences, Director of the Contract Manufacturing Department at Novalik-Pharm. - As you know, natural venotonics are divided into two main groups. The first group is preparations based on horse chestnut. The second is venotonics containing bioflavonoids Diosmin and Hesperidin, which are obtained mainly from citrus peels. The innovation of the Austrian company Sanwezza Lab GmbH is that they have created a new powerful formula - “three in one”, that is, they have combined the active components of two main groups of venotonics in one preparation. The drug “Venoda” includes horse chestnut seed extract (with a high concentration of Aescin), Diosmin and Hesperidin, which enhance and complement each other’s action.”

Thanks to the combination of the three most effective venotonic natural substances, the developers were able to present the consumer with a new original product that has a more powerful and complex effect on the venous system compared to other venotonics. The unique combination of Escin, Diosmin and Hesperidin determines the venotonic, decongestant, antithrombotic and analgesic effects of the drug. Thus, “Venoda” affects almost all stages of the development of venous diseases.

The ease of administration and cost-effectiveness of the Venoda drug are also obvious: it is advisable to purchase one package of the “three-in-one” drug rather than two packages of different types of medicines – containing Escin and Diosmin with Hesperidin. Despite the uniqueness of the drug, its price will be lower than most analogues and is affordable for most buyers.

The tender for the production of an innovative drug based on Austrian development was won by the Ukrainian company Novalik-Pharm. The drug "Venoda" is produced on the basis of standardized plant extracts from Eusa and Naturex (France). The official distributor of the drug, the Pharmplaneta company, reports that Venoda is already available in the national retail chain Pani Apteka and the online store paniapteka.ua, and will soon be available in all pharmacy chains in Ukraine.

About the distributor company

The Pharmplanet company is an expert in the pharmaceutical market, a national service company that provides a full range of services: registration, logistics, marketing and promotion, distribution of medicines, medical products, cosmetics, dietary supplements. The company's partners include more than 300 large manufacturers. Pharmplanet promotes its own brands: Sitoprostat, Hepanase, Declimans, Silenor, Apiproposol, DryVir, Tribustim, as well as